Illumina announced it has completed its acquisition of SomaLogic, adding data-driven proteomics capabilities to broaden its multiomics portfolio and expand customer access to protein insights at scale. The company positioned the deal as a key step in the multiomics strategy it outlined in 2024, aiming to pair SomaLogic’s proteomics technology with Illumina’s global reach, sequencing ecosystem, and software to accelerate discovery and improve health care outcomes.
Illumina said customers will be able to integrate SomaLogic’s SomaScan platform with Illumina offerings, including Illumina Protein Prep, SomaSignal Tests, DRAGEN software, and Illumina Connected Multiomics, to generate richer multiomic datasets with greater workflow flexibility. The company added that it plans to maintain continuity for SomaLogic products and services as it integrates the portfolio into Illumina’s roadmap, while continuing to support existing SomaLogic customers and partnerships, including service providers using an array-based readout.
The companies have worked together since late 2021 on bringing the SomaScan Proteomics Assay onto Illumina’s high-throughput next-generation sequencing platforms. Illumina said the completed acquisition builds on that co-development relationship and strengthens its position in what it described as a large and growing proteomics market.
Illumina acquired SomaLogic and certain other assets from Standard BioTools for $350 million in cash paid at closing, subject to customary adjustments, plus up to $75 million tied to near-term performance-based milestones and performance-based royalties. Illumina said it funded the transaction with cash on hand and plans to discuss the financial implications on its upcoming earnings call scheduled for February 5, 2026.
KEY QUOTES
“Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024. By combining SomaLogic’s highly differentiated proteomics technology with Illumina’s industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients.”
Jacob Thaysen, Chief Executive Officer, Illumina
